According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “
Other equities analysts have also issued reports about the company. LADENBURG THALM/SH SH reiterated a buy rating and issued a $9.00 price objective on shares of Armata Pharmaceuticals in a research report on Monday, July 15th. HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research report on Thursday, August 15th.
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.40).
An institutional investor recently bought a new position in Armata Pharmaceuticals stock. BlackRock Inc. bought a new position in shares of Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 11,264 shares of the company’s stock, valued at approximately $45,000. BlackRock Inc. owned about 0.47% of Armata Pharmaceuticals at the end of the most recent quarter.
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.
Featured Story: Stochastic Momentum Index (SMI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.